Drag & drop elements to this column Made with Alai JA K IN H IB ITOR Introduction to Jakavi (Ruxolitinib) Jakavi Tablet contains Ruxolitinib , an oral JAK1/JAK2 inhibitor that modulates the JAK-STAT signaling pathway involved in blood cell production and immune regulation. Prescription-only medicine — initiation and monitoring require a qualified healthcare professional. Active Ingredient Ruxolitinib — selective inhibitor of JAK1 and JAK2 kinases Mechanism of Action Modulates JAK-STAT signaling pathways controlling blood cell production and immune regulation Indications Hematologic and bone marrow disorders: myelofibrosis, polycythemia vera, and GVHD Made with Alai P R ODU CT OV E R V IE W Product Overview & Classification Jakavi (Ruxolitinib) — Oral JAK1/JAK2 inhibitor for targeted kinase pathway blockade GE N E R IC N A M E Ruxolitinib Active pharmaceutical ingredient; INN- designated small molecule kinase inhibitor P H A R M AC OLOGIC A L C LA SS JAK1/JAK2 Inhibitor Selective inhibitor of Janus-associated kinase 1 and 2 signaling pathways DOSAGE FOR M Oral Tablet Multiple strengths available; dose individualized by indication, response, and clinical status Made with Alai JA KAV I (R U XOLIT IN IB) · JA K1 /JA K2 IN H IB ITOR Clinical Indications H E M ATOLOGIC M A LIGN A N CY Myelofibrosis Bone marrow disorder with aberrant hematopoiesis and progressive fibrosis, resulting in dysregulated blood cell production and extramedullary hematopoiesis. M YE LOP R OLIFE R AT IV E N E OP LA SM Polycythemia Vera Clonal myeloproliferative neoplasm characterized by uncontrolled erythrocyte production, with elevated hematocrit and associated thromboembolic risk. IM M U N E- M E DIAT E D C OM P LIC AT ION Graft-Versus-Host Disease (GVHD) Select cases of immune-mediated allogeneic reaction following stem cell transplantation, where donor immune cells target host tissue. Indication is determined by individual patient clinical assessment and diagnostic evaluation. Made with Alai JA K1 /JA K2 IN H IB IT ION Mechanism of Action Ruxolitinib selectively inhibits JAK1 and JAK2 kinases , blocking dysregulated signaling responsible for abnormal blood cell proliferation and pathological immune activation. JAK1/JAK2 Pathway — Downstream Effects H E M ATOP OIE SIS Blood Cell Production Regulates myeloid and erythroid progenitor differentiation; inhibition attenuates abnormal proliferation in myeloproliferative neoplasms. IM M U N E M ODU LAT ION Immune System Activation Modulates T -cell and NK-cell activity; reduces alloimmune responses relevant in graft-versus-host disease settings. IN FLA M M ATORY SIGN A LIN G Cytokine Release Attenuation Suppresses pro-inflammatory cytokine signaling (IL-6, IFN- γ , TNF- α ) driving splenomegaly, constitutional symptoms, and systemic inflammation. Made with Alai Made with Alai Made with Alai Precautions Safety Considerations P R E-T R E AT M E N T WOR KU P Clinical Assessment Review comorbidities, full medication reconciliation, history of prior infections, and evaluation of hepatic and renal function. ON GOIN G M ON ITOR IN G Safety Surveillance Serial CBCs required. Active surveillance for signs of infection. Review and update vaccination status before initiating therapy. SP E C IA L P OP U LAT ION S Individualized Evaluation Pregnant or breastfeeding individuals require individualized risk-benefit evaluation prior to initiating treatment. Made with Alai Made with Alai